| Haemophilus influenza causes infections that are a major cause of morbidity and mortality in young children spreading through droplets. Children below 5 years of age are at highest risk of the disease & is rarely seen after 5 years of age. Every year globally around 3 to 5 lakhs children die due to H. influenza type b disease. HIB vaccines are safe and highly effective. |
| According to Dr. Cyrus Poonawalla, Chairman, Serum Institute of India Ltd.: "HibPRO has undergone series of clinical trials to prove its efficacy and safety in comparison with commercially available Hib conjugate vaccines. With the launch of HibPRO serum can extend the benefits of Pentavalent or Quadravalent vaccines at a very affordable price. These benefits are mainly fewer numbers of injections, lesser pain to the child and protection against multiple diseases such as H. influenza type b, Hepatitis-B, Diphtheria, Pertussis and Tetanus in one injection." |
| About Serum Institute of India: Serum Institute of India is the World's largest DTP (Triple) and measles vaccine manufacturer and has been responsible for bringing down the prices of Hepatitis-B vaccines in India. The Company's products are exported to over 140 countries worldwide. According to a survey conducted by Indian Association of Biotechnology Led Enterprises (ABLE) & BioSpectrum for the year 2006-07, Serum Institute retained the No. 1 slot in biotech business. |
| Serum institute has shelved its plans for an IPO as it does not require funds for acquisitions etc. Serum Institute will expand organically with its own funds. |
Top Section
Explore Business Standard